Suppr超能文献

局部进展期胃食管癌的围手术期治疗:当前的争议与治疗共识

Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care.

作者信息

Sehdev Amikar, Catenacci Daniel V T

机构信息

Department of Medicine, Section of Hematology Oncology, University of Chicago, 5841 S, Maryland Avenue, MC 2115, Chicago, IL 60637, USA.

出版信息

J Hematol Oncol. 2013 Sep 5;6:66. doi: 10.1186/1756-8722-6-66.

Abstract

Gastroesophageal cancer (GEC) remains a challenging problem in oncology. Anatomically, GEC is comprised of distal gastric adenocarcinoma (GC), classically associated with Helicobacter Pylori, while proximal esophagogastric adenocarcinoma (EGJ AC) has increased significantly in incidence over the past years. Despite contrasting etiologies, histologies, and molecular phenotypes of distal and proximal GEC, in many cases perioperative (and metastatic) treatment strategies converge to similar approaches. For patients undergoing curative intent surgery, advances in perioperative chemotherapy and/or chemoradiotherapy, either before and/or after surgery, have demonstrated improved survivals compared to surgery alone. This review focuses on how the 'boundary' of the Z-line and/or the anatomical distinction of 'proximal' (EGJ) vs. 'distal' (GC) cancer has led to diverse inclusion/exclusion criteria for clinical trial enrollment, embodying various combinations of chemotherapy and radiation before and/or after surgery. Supporting evidence of each of these approaches consequently has led to a number of varying practices by geographical region and Institution/Physician, based on differing experience, preference, and clinical circumstance. Adequate direct comparison of these approaches is lacking currently, but data from a number of concerted efforts should be available in the next years to further direct best standards of care. Introduction of biologically targeted agents, namely anti-angiogenics and anti-HER family therapeutics are being evaluated to determine whether further therapeutic gains can be realized over classic cytotoxic chemotherapy alone (with/without radiotherapy). To date, novel molecularly targeted agents have yet to demonstrate benefit in this setting. In the following comprehensive review we will address the intricacies of perioperative treatment of locally advanced GEC, with focus on clinical trials supporting the diverse set of perioperative multidisciplinary approaches.

摘要

在肿瘤学领域,胃食管癌(GEC)仍然是一个具有挑战性的难题。从解剖学角度来看,GEC包括远端胃腺癌(GC),其传统上与幽门螺杆菌相关,而近端食管胃腺癌(EGJ AC)在过去几年中发病率显著上升。尽管远端和近端GEC在病因、组织学和分子表型方面存在差异,但在许多情况下,围手术期(以及转移性)治疗策略却趋于相似。对于接受根治性手术的患者,术前和/或术后围手术期化疗和/或放化疗的进展表明,与单纯手术相比,生存率有所提高。本综述重点关注Z线的“边界”和/或“近端”(EGJ)与“远端”(GC)癌症的解剖学差异如何导致临床试验入组的不同纳入/排除标准,体现了手术前后化疗和放疗的各种组合。因此,基于不同的经验、偏好和临床情况,这些方法中的每一种的支持证据都导致了不同地区以及机构/医生的多种不同做法。目前缺乏对这些方法的充分直接比较,但未来几年应该会有来自多项协同努力的数据,以进一步指导最佳治疗标准。正在评估生物靶向药物的引入,即抗血管生成药物和抗HER家族治疗药物,以确定与单纯经典细胞毒性化疗(联合/不联合放疗)相比,是否能实现进一步的治疗获益。迄今为止,新型分子靶向药物在这种情况下尚未显示出益处。在以下全面综述中,我们将探讨局部晚期GEC围手术期治疗的复杂性,重点关注支持多种围手术期多学科方法的临床试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/070a/3844370/2c2e15942716/1756-8722-6-66-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验